PRELUDE THERAPEUTICS INCORPORATED
175 Innovation Boulevard
Wilmington, Delaware 19805
May 1, 2024
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attention: Alan Campbell
| Re: | Prelude Therapeutics Incorporated, Registration Statement on Form S-3 (File No. 333-277123) filed February 16, 2024. |
Requested Date: May 3, 2024
Requested Time: 4:30 PM Eastern Time
Ladies and Gentlemen:
Prelude Therapeutics Incorporated (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to declare the above-captioned Registration Statement on Form S-3 effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable, or at such later time as the Registrant may orally request via telephone call to the staff of the Commission.
The Registrant hereby authorizes Robert Freedman or Julia Forbess, both of whom are attorneys with the Registrant’s outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration.
The Registrant requests that it be notified of such effectiveness by a telephone call to Mr. Freedman at (206) 389-4524 or, in his absence, to Ms. Forbess at (415) 875-2420.
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]
| Sincerely, | ||
| Prelude Therapeutics Incorporated | ||
| By: | /s/ Bryant Lim | |
| Bryant Lim | ||
| Chief Legal Officer, Corporate Secretary, and Interim Chief Financial Officer | ||
| cc: | Kris Vaddi, Chief Executive Officer |
Prelude Therapeutics Incorporated
Robert Freedman, Esq.
Julia Forbess, Esq.
Fenwick & West LLP